The authors reply

Affiliations

¹ Providence Medical Research Center, Providence Inland Northwest Health, Spokane, Washington, USA; Nephrology Division, Kidney Research Institute, Seattle, Washington, USA; Institute of Translational Health Sciences, University of Washington, Seattle, Washington, USA. Electronic address: katherine.tuttle@providence.org.
² Medical and Science Department, NovoNordisk A/S, Medical and Science, Søborg, Denmark.
³ Division of Nephrology, Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada.
⁴ Département d'Endocrinologie, Diabétologie et Nutrition, Nantes Université, l'Institut du Thorax, Nantes, France.
⁵ Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel; Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; Regeneron Pharmaceuticals Inc., New York, New York, USA.
⁶ Biostatistics Department, Novo Nordisk A/S, Biostatistics, Søborg, Denmark.
⁷ Diabetes Research Unit, Swansea University, Swansea, UK.

Comment

Katherine R Tuttle et al. Kidney Int. 2023 Sep.

. 2023 Sep;104(3):619.

doi: 10.1016/j.kint.2023.06.008.

¹ Providence Medical Research Center, Providence Inland Northwest Health, Spokane, Washington, USA; Nephrology Division, Kidney Research Institute, Seattle, Washington, USA; Institute of Translational Health Sciences, University of Washington, Seattle, Washington, USA. Electronic address: katherine.tuttle@providence.org.
² Medical and Science Department, NovoNordisk A/S, Medical and Science, Søborg, Denmark.
³ Division of Nephrology, Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada.
⁴ Département d'Endocrinologie, Diabétologie et Nutrition, Nantes Université, l'Institut du Thorax, Nantes, France.
⁵ Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel; Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; Regeneron Pharmaceuticals Inc., New York, New York, USA.
⁶ Biostatistics Department, Novo Nordisk A/S, Biostatistics, Søborg, Denmark.
⁷ Diabetes Research Unit, Swansea University, Swansea, UK.

No abstract available

Comment on

Routine care data and the benefits of GLP1 receptor agonists on slowing kidney function decline.
Xu Y, Faucon AL, Fu EL, Carrero JJ. Xu Y, et al. Kidney Int. 2023 Sep;104(3):618-619. doi: 10.1016/j.kint.2023.06.009. Kidney Int. 2023. PMID: 37599022 No abstract available.